The Keosys Blog

Expert insights into medical imaging in clinical trials.
Lucie Rivière
Considering the Latest in Drug Development

Every day, scientists and researchers work to improve our health. Today more..

Central Review According to iRECIST in Cancer Immunotherapy Clinical Trials

This is an excerpt from our free eBook “Imaging and Read Criteria in Cancer..

Keo-Tales: Looking Back and Looking Forward

Keosys is an imaging solutions provider supporting biopharmaceutical..

Read Criteria and the Evaluation of Antitumor Responses With Immunotherapeutic Agents

This is an excerpt from our free eBook “Imaging and Read Criteria in Cancer..

Project Manager Stephanie Graf Joins the Keosys Team in the US

We are pleased to welcome Stephanie Graf to our Project Management team in..

Interview: Cancer Insight Leverages a Surgical Oncologist's Long Commitment to Service and Research

We recently spoke with George E. Peoples, M.D., founder and Chief Executive..

Interview: Global Perspectives from a Global Powerhouse, Syneos Health

We recently spoke with Patrick Nealon, Executive Vice President and General..

Interview: OncoBay Clinical Redefines What's Possible for CROs

We recently spoke with OncoBay Clinical executives Krystyna Kowalczyk, CEO,..

Interview: Orano Med and Leading in Nuclear Medicine

We recently spoke with Jason Hurt, MD, chief medical officer for Orano Med

The Importance of Imaging Review Charters in Clinical Trials

When imaging is part of a clinical trial, two unique documents must be..

The Importance of Imaging Acquisition Guidelines in Clinical Trials

There are numerous documents that demand serious attention as a clinical..

AI in Medical Imaging: The Kidney Tumor Segmentation Challenge

Precise characterization of the kidney and kidney tumor characteristics is..

The Challenges of Imaging Biomarker Development

Imaging biomarkers are often pivotal components of a clinical trial, from ..

What is a Medical Imaging CRO?

In the life science industry, there are biopharma companies who carry out..

More Posts

New call-to-action